HS
SRNE

HighVista Strategies’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

HighVista Strategies’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,000
Closed -$174K – 148
2021
Q2 		$174K Hold
18,000
– – 0.12% 79
2021
Q1 		$149K Hold
18,000
– – 0.11% 85
2020
Q4 		$123K Hold
18,000
– – 0.08% 78
2020
Q3 		$201K Buy
+18,000
New +$165K 0.15% 71

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HighVista Strategies's SRNE Position: Q3 2021 in Review

HighVista Strategies sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2021, closing a stake of 18,000 shares — an estimated $174K sold.

HighVista Strategies first reported a position in SRNE in Q3 2020 and held it in 4 quarters. The position peaked at $201K in Q3 2020. 220 funds tracked by Wall St. Rank hold SRNE as of Q3 2021.

  • HighVista Strategies reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • HighVista Strategies sold 18,000 Sorrento Therapeutics, Inc. shares in Q3 2021, an estimated $174K.
  • HighVista Strategies first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 4 quarters.
  • HighVista Strategies's Sorrento Therapeutics, Inc. position peaked at $201K in Q3 2020.
  • 220 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2021.

Based on HighVista Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.